

Bevacizumab PK Fact Sheet

Reviewed May 2024

Page 1 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

<i>Generic Name</i>	Bevacizumab.
<i>Trade Name</i>	Avastin®.
<i>Class</i>	Antineoplastic agents, monoclonal antibody.
<i>Molecular Weight</i>	~149 kDa ¹ .

Summary of Key Pharmacokinetic Parameters

<i>Linearity/non-linearity</i>	Linear pharmacokinetics over the dose range 1-10 mg/kg.
<i>Steady state</i>	Predicted >90% of steady-state concentration after 84 days.
<i>Plasma half-life</i>	20 days (estimated).
<i>C_{max}</i>	Not reported.
<i>C_{min}</i>	80.3 µg/mL (Pop PK).
<i>AUC</i>	Not reported.
<i>Bioavailability</i>	Administered IV.
<i>Absorption</i>	Administered IV.
<i>Protein Binding</i>	Not reported.
<i>Volume of Distribution</i>	2.9 L (central VoD).
<i>Renal Clearance</i>	Not a major route of bevacizumab clearance.
<i>Renal Impairment</i>	Not investigated as kidneys not a major route of bevacizumab metabolism or elimination.
<i>Hepatic Impairment</i>	Not investigated as liver not a major route of bevacizumab metabolism or elimination.

Metabolism and Distribution

<i>Metabolised by</i>	Catabolised through non-specific pathways.
<i>Inducer of</i>	None reported.
<i>Inhibitor of</i>	None reported.
<i>Transported by</i>	None reported.

References

Unless otherwise stated (see below), information is from:

Avastin Summary of Product Characteristics, Roche, December 2022.

Bevacizumab PK Fact Sheet

Reviewed May 2024

Page 2 of 2

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Avastin US Prescribing Information Genentech Inc, September 2022.

1. Bevacizumab. Bethesda (MD): National Institute of Child Health and Human Development, Drugs and Lactation Database (LactMed®) [Internet]. 2006-. [Updated 15/01/2024, accessed 27/02/2024]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501731/>